Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2672 (LINC02672)
- Target
- LINC02672
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic lncRNA (lincRNA); a subclass of lncRNA originating from regions between protein-coding genes
01
Overview
Long intergenic non-protein coding RNA 2672 (LINC02672, also known as OIN1 or ovarian cancer long intergenic noncoding RNA 1) is a long non-coding RNA transcribed from chromosome 10q21.1 and highly upregulated in ovarian cancer tissues compared with normal ovaries[1][2][3]. OIN1 promotes the proliferation and suppresses apoptosis of ovarian cancer cells via modulation of genes such as RASSF5 and ADORA1, supporting its role as a tumor-promoting lincRNA and potential molecular target for therapeutic intervention[1][2][3]. Experimental silencing with siRNA impairs tumor growth and increases apoptosis in preclinical models, positioning LINC02672 as an emerging candidate in ovarian cancer management, though no approved drugs directly target it and its precise mechanisms remain under investigation[1][2][3].
- Other names
- OIN1Ovarian cancer long intergenic noncoding RNA 1NONHSAT013448 (NONCODE database ID)
02
Mechanism of action
RNA interference (RNAi): siRNA-mediated knockdown of LINC02672/OIN1 suppresses expression, resulting in inhibition of cell proliferation and induction of apoptosis
03
Biological functions
Modulation of apoptosis (suppresses cell death in ovarian cancer cells)Promotion of cell proliferationMay also affect regulation of gene expression relevant to cancer, including downstream apoptotic regulators such as RASSF5 and ADORA1Possible involvement in homologous recombination or immune modulation (inferred from endogenous retrovirus-like sequence origin, though not fully established)
04
Disease associations
Cancer (primarily ovarian cancer, as a tumor-promoting factor and therapeutic target candidate)
05
Safety considerations
As an experimental target, specific safety concerns for therapies targeting LINC02672/OIN1 are not established in clinical use.General challenges for RNA-based therapies include off-target effects and delivery efficiency.In vivo use of siRNA targeting OIN1 has shown tumor reduction in animal studies with no major reported adverse effects, though human data are unavailable.
06
Interacting drugs
Small interfering RNAs (siRNAs) specific to OIN1
07
Biomarkers
Overexpression of LINC02672/OIN1 in ovarian cancer tissue and cell lines serves as a potential biomarker for diagnosis or patient selection in research settings
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2672 (LINC02672).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2672 (LINC02672).